Upgrade to OUTPERFORM from NEUTRAL. Our upgrade is driven by a significant share price decline, improvement in pricing and sufficient liquid assets to prepare for commercialisation in the US. While US reimbursement decision is a binary event and represents uncertainty for this region, the health economic value of this test is of significant value to healthcare systems world-wide. We see a potential takeover attempt from existing or new investors as a possible scenario. Thus, current trading leve ....
16 Nov 2017
Good entry point for the long term investor
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Good entry point for the long term investor
Epigenomics AG (0QXH:LON) | 0 0 0.0% | Mkt Cap: 24.5m
- Published:
16 Nov 2017 -
Author:
Tim Franklin -
Pages:
5
Upgrade to OUTPERFORM from NEUTRAL. Our upgrade is driven by a significant share price decline, improvement in pricing and sufficient liquid assets to prepare for commercialisation in the US. While US reimbursement decision is a binary event and represents uncertainty for this region, the health economic value of this test is of significant value to healthcare systems world-wide. We see a potential takeover attempt from existing or new investors as a possible scenario. Thus, current trading leve ....